Logo
x

Search

Subscribe Now

Mirati

Mirati’s Krazati (adagrasib) Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Advanced KRAS-Mutated Colorectal Cancer

Mirati’s Krazati (adagrasib) Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Advanced KRAS-Mutated Col...

  • December 22, 2022
Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer

Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer

  • May 20, 2022
PharmaShots Weekly Snapshots (October 04 - 08, 2021)

PharmaShots Weekly Snapshots (October 04 - 08, 2021)

  • October 8, 2021
PharmaShots Weekly Snapshots (September 20 - 24, 2021)

PharmaShots Weekly Snapshots (September 20 - 24, 2021)

  • September 24, 2021
PharmaShots Weekly Snapshots (May 24 - 28, 2021)

PharmaShots Weekly Snapshots (May 24 - 28, 2021)

  • May 28, 2021
QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer

QIAGEN Collaborates with Mirati to Develop KRASG12C CDx for Non-Small Cell Lung Cancer

  • May 26, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.